| John Conti, MD | |
|
1 Clara Maass Dr Ste 200, Belleville, NJ 07109-3550 | |
| (973) 751-8880 | |
| (973) 751-8950 |
| Full Name | John Conti |
|---|---|
| Gender | Male |
| Speciality | Medical Oncology |
| Experience | 38 Years |
| Location | 1 Clara Maass Dr Ste 200, Belleville, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811973084 | NPI | - | NPPES |
| 6761305 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 25MA05012600 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Atlantic Home Care And Hospice | Morristown, NJ | Hospice |
| Hackensackumc Mountainside | Montclair, NJ | Hospital |
| Clara Maass Medical Center | Belleville, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| New Jersey Cancer Care, Pa | 3971603788 | 10 |
News Archive
The city of Cambridge, a global hub for research and healthcare innovation, is to host Cambridge BioTech Week from 24-28 June 2019.
Arena Pharmaceuticals, Inc. today announced that Eisai Inc. will market lorcaserin for obesity and weight management in the United States following U.S. Food and Drug Administration (FDA) approval under the terms of a marketing and supply agreement between Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., and Eisai. Lorcaserin, which Arena discovered and has developed for weight management, is intended for obese patients as well as overweight patients who have at least one weight-related co-morbid condition.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an overall survival benefit would be the most influential factor for three-quarters of surveyed European oncologists in their decision to prescribe a novel agent ahead of Avastin for the treatment of breast cancer.
Only a small fraction of people with very high cholesterol can attribute their condition to a genetic mutation related to familial hypercholesterolemia, but individuals with these mutations face a high risk of developing early-onset coronary artery disease, according to research presented at the American College of Cardiology's 65th Annual Scientific Session.
Obesity is one of the biggest threats to child health. Genetics, decreases in physical activity, increases in television watching, and consumption of fast food are factors that have led to an increase of childhood obesity in the United States. Excessive consumption of sugar sweetened drinks may also be a key factor.
› Verified 3 days ago
| Entity Name | New Jersey Cancer Care, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447315502 PECOS PAC ID: 3971603788 Enrollment ID: O20070710000160 |
News Archive
The city of Cambridge, a global hub for research and healthcare innovation, is to host Cambridge BioTech Week from 24-28 June 2019.
Arena Pharmaceuticals, Inc. today announced that Eisai Inc. will market lorcaserin for obesity and weight management in the United States following U.S. Food and Drug Administration (FDA) approval under the terms of a marketing and supply agreement between Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., and Eisai. Lorcaserin, which Arena discovered and has developed for weight management, is intended for obese patients as well as overweight patients who have at least one weight-related co-morbid condition.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an overall survival benefit would be the most influential factor for three-quarters of surveyed European oncologists in their decision to prescribe a novel agent ahead of Avastin for the treatment of breast cancer.
Only a small fraction of people with very high cholesterol can attribute their condition to a genetic mutation related to familial hypercholesterolemia, but individuals with these mutations face a high risk of developing early-onset coronary artery disease, according to research presented at the American College of Cardiology's 65th Annual Scientific Session.
Obesity is one of the biggest threats to child health. Genetics, decreases in physical activity, increases in television watching, and consumption of fast food are factors that have led to an increase of childhood obesity in the United States. Excessive consumption of sugar sweetened drinks may also be a key factor.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John Conti, MD 1 Clara Maass Dr Ste 200, Belleville, NJ 07109-3550 Ph: (973) 751-8880 | John Conti, MD 1 Clara Maass Dr Ste 200, Belleville, NJ 07109-3550 Ph: (973) 751-8880 |
News Archive
The city of Cambridge, a global hub for research and healthcare innovation, is to host Cambridge BioTech Week from 24-28 June 2019.
Arena Pharmaceuticals, Inc. today announced that Eisai Inc. will market lorcaserin for obesity and weight management in the United States following U.S. Food and Drug Administration (FDA) approval under the terms of a marketing and supply agreement between Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., and Eisai. Lorcaserin, which Arena discovered and has developed for weight management, is intended for obese patients as well as overweight patients who have at least one weight-related co-morbid condition.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an overall survival benefit would be the most influential factor for three-quarters of surveyed European oncologists in their decision to prescribe a novel agent ahead of Avastin for the treatment of breast cancer.
Only a small fraction of people with very high cholesterol can attribute their condition to a genetic mutation related to familial hypercholesterolemia, but individuals with these mutations face a high risk of developing early-onset coronary artery disease, according to research presented at the American College of Cardiology's 65th Annual Scientific Session.
Obesity is one of the biggest threats to child health. Genetics, decreases in physical activity, increases in television watching, and consumption of fast food are factors that have led to an increase of childhood obesity in the United States. Excessive consumption of sugar sweetened drinks may also be a key factor.
› Verified 3 days ago
Dr. Etan B Spira, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 5 Franklin Ave, Suite 109, Belleville, NJ 07109 Phone: 973-759-7240 Fax: 973-759-7243 | |
Dr. Jimmy Martins Paulo, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1 Clara Maass Dr Ste 202, Belleville, NJ 07109 Phone: 973-450-2433 Fax: 973-450-2434 | |
Hemalatha Vasireddy, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1 Clara Maass Dr Ste 200, Belleville, NJ 07109 Phone: 973-751-8880 Fax: 973-751-8950 | |
Dr. Mario A Criscito, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 50 Newark Ave, Suite 204, Belleville, NJ 07109 Phone: 973-450-2158 Fax: 973-450-2027 | |
John Daconti, DO Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 77 Newark Ave, Suite 3 & 4, Belleville, NJ 07109 Phone: 973-528-2160 Fax: 973-528-2165 | |
Jaxon James Fernandes, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1 Clara Maass Dr, Belleville, NJ 07109 Phone: 973-450-2000 | |
Dr. Dianne Walker, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 303 Belmont Ave, Belleville, NJ 07109 Phone: 973-751-4818 Fax: 973-751-4886 |